Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06031688 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 266 → 278 locations Eligibility criteria expanded, about 14 words · Secondary endpoints: details revised at 4 of 5 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 4 of 5 entries
  2. Study sites: 267 to 266v9
  3. Study sites: 240 to 267 Completion date: May 31, 2029 to May 31, 2028 · Eligibility criteria expanded, about 31 words · Secondary endpoints revised (5) · 2 morev8 Show 5 more changesShow less
    • Completion date: May 31, 2029 to May 31, 2028
    • Eligibility criteria expanded, about 31 words
    • Secondary endpoints revised (5)
    • Study description expanded, about 43 words
    • Collaborators: 3 to 1

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 233 to 240v7
  5. Study sites: 222 to 233v6
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 222 · Start date changed from estimate of Jul 15, 2024 to Aug 8, 2024 · Collaborators: 1 to 3v5 Show 3 more changesShow less
    • Study sites: 0 to 222
    • Start date changed from estimate of Jul 15, 2024 to Aug 8, 2024
    • Collaborators: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: May 15, 2024 to Jul 15, 2024v4
  3. Start date: Mar 15, 2024 to May 15, 2024v3
  4. Start date: Jan 6, 2024 to Mar 15, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Trial Details
NCT Number NCT06031688
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov